Cyhoeddiad
2025
- Oliver, J. et al. 2025. Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients. Cancer Immunology, Immunotherapy 75 (1) 3. (10.1007/s00262-025-04218-6)
2023
- Milutinovic, S. and Gallimore, A. 2023. The link between T cell activation and development of functionally useful tumour-associated high endothelial venules. Discovery Immunology 2 (1) kyad006. (10.1093/discim/kyad006)
2022
- Milutinovic, S. et al. 2022. Three-dimensional imaging reveals immune-driven tumor-associated high endothelial venules as a key correlate of tumor rejection following depletion of regulatory T cells. Cancer Research Communications 2 (12), pp.1641-1656. (10.1158/2767-9764.CRC-21-0123)
- Lauder, S. N. et al. 2022. Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion. British Journal of Cancer 127 , pp.1595–1602. (10.1038/s41416-022-01917-0)
2021
- Milutinovic, S. et al. 2021. The dual role of high endothelial venules in cancer progression versus immunity. Trends in Cancer 7 (3), pp.214-225. (10.1016/j.trecan.2020.10.001)
- Lauder, S. N. et al. 2021. Using methylcholanthrene-induced fibrosarcomas to study tumor immunology. In: Methods in Cell Biology. Vol. 163, Elsevier. , pp.59-75. (10.1016/bs.mcb.2020.09.007)
2020
- Pires, A. et al. 2020. Immune remodelling of the extracellular matrix drives loss of cancer stem cells and tumor rejection. Cancer Immunology Research 8 (12), pp.1520 - 1531. (10.1158/2326-6066.CIR-20-0070)
- Lauder, S. N. et al. 2020. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3. Journal for ImmunoTherapy of Cancer 8 (2) e000693. (10.1136/jitc-2020-000693)
- Milutinovic, S. 2020. Investigating the role of high endothelial venules in cancer immunity. PhD Thesis , Cardiff University.
Articles
- Oliver, J. et al. 2025. Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients. Cancer Immunology, Immunotherapy 75 (1) 3. (10.1007/s00262-025-04218-6)
- Milutinovic, S. and Gallimore, A. 2023. The link between T cell activation and development of functionally useful tumour-associated high endothelial venules. Discovery Immunology 2 (1) kyad006. (10.1093/discim/kyad006)
- Milutinovic, S. et al. 2022. Three-dimensional imaging reveals immune-driven tumor-associated high endothelial venules as a key correlate of tumor rejection following depletion of regulatory T cells. Cancer Research Communications 2 (12), pp.1641-1656. (10.1158/2767-9764.CRC-21-0123)
- Lauder, S. N. et al. 2022. Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion. British Journal of Cancer 127 , pp.1595–1602. (10.1038/s41416-022-01917-0)
- Milutinovic, S. et al. 2021. The dual role of high endothelial venules in cancer progression versus immunity. Trends in Cancer 7 (3), pp.214-225. (10.1016/j.trecan.2020.10.001)
- Pires, A. et al. 2020. Immune remodelling of the extracellular matrix drives loss of cancer stem cells and tumor rejection. Cancer Immunology Research 8 (12), pp.1520 - 1531. (10.1158/2326-6066.CIR-20-0070)
- Lauder, S. N. et al. 2020. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3. Journal for ImmunoTherapy of Cancer 8 (2) e000693. (10.1136/jitc-2020-000693)
Book sections
- Lauder, S. N. et al. 2021. Using methylcholanthrene-induced fibrosarcomas to study tumor immunology. In: Methods in Cell Biology. Vol. 163, Elsevier. , pp.59-75. (10.1016/bs.mcb.2020.09.007)
Thesis
- Milutinovic, S. 2020. Investigating the role of high endothelial venules in cancer immunity. PhD Thesis , Cardiff University.